We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gene Mutations Found For Malignant Brain Tumor

By LabMedica International staff writers
Posted on 23 Aug 2011
Genetic mutations found on chromosomes could increase the chances for an effective combination of drug therapy to treat the second most common type of brain tumor. More...


The primary cancer genes involved in the development of oligodendrogliomas (ODs) were known to be on the chromosomes 1 and 19, but not the particular gene information, which was found using whole genome sequencing technology.

Scientists at Duke University Medical Center (Durham, NC, USA) and Johns Hopkins University (Baltimore, MD, USA) performed exomic sequencing of seven malignant brain tumors. They sequenced the coding exons of 20,687 genes in DNA from the seven anaplastic ODs using the HiSeq platform (Illumina, San Diego, CA, USA).

The investigators found the protein capicua homolog gene (CIC) on chromosome 19 and far upstream element-binding protein 1 gene (FUBP1) on chromosome 1 based on an initial study of seven oligodendrogliomas and uncovered six mutations and two mutations, respectively, in the seven tumors. Further study of 27 more of these tumors showed that there were 12 and 3 mutations of CIC and FUBP1, respectively. The two genes were rarely mutated in other types of cancers, indicating that they are oligodendroglioma-specific genes. The genes they identified are tumor suppressor genes. The cancer-related pathways that involve these genes could become targets for future treatments.

Hai Yan, MD, PhD, co-corresponding author of the study, said, "The team used whole genome sequencing technology so that no genes would be excluded, and we found to our surprise that one gene, on chromosome 19, was mutated in six out of the seven initial tumor specimens we sequenced. A mutation frequency of 85% is very high." Another very important feature is that the genes could be used as biomarkers to distinguish this type of cancer from other types of brain tumors. The study was published on August 4, 2011 in Science.

Related Links:
Duke University Medical Center
Johns Hopkins University
illumina



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.